José A Sanches

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128581/publications.pdf

Version: 2024-02-01

218592 138417 3,697 112 26 58 citations g-index h-index papers 114 114 114 3364 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort. International Journal of Dermatology, 2022, 61, 442-454.	0.5	5
2	Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population. International Journal of Dermatology, 2022, 61, .	0.5	3
3	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 2022, 140, 419-437.	0.6	58
4	Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital. Anais Brasileiros De Dermatologia, 2022, 97, 14-21.	0.5	7
5	The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome. International Journal of Molecular Sciences, 2022, 23, 936.	1.8	6
6	Case for diagnosis. Erythematous-violaceous reticulated plaques on the breasts. Anais Brasileiros De Dermatologia, 2022, , .	0.5	0
7	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*. British Journal of Dermatology, 2021, 184, 722-730.	1.4	39
8	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*. British Journal of Dermatology, 2021, 184, 524-531.	1.4	18
9	IFNâ€Î³ reshapes monocyte responsiveness in Sezary syndrome. International Journal of Dermatology, 2021, 60, e3-e6.	0.5	1
10	Absence of specific cutaneous manifestations of severe acute respiratory syndrome coronavirus 2 in a reference center in Brazil. Journal of the American Academy of Dermatology, 2021, 84, e67.	0.6	7
11	Primary cutaneous CD30â€positive T cell lymphoproliferative disorders associated with polymethylmethacrylate: An unfortunate coincidence or a causal relationship?. Dermatologic Therapy, 2021, 34, e14824.	0.8	0
12	Different aspects and variants of mycosis fungoides in a single patient. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 1-4.	0.2	1
13	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. European Journal of Cancer, 2021, 148, 411-421.	1.3	27
14	Mycosis fungoides and SÃ $@$ zary syndrome: focus on the current treatment scenario. Anais Brasileiros De Dermatologia, 2021, 96, 458-471.	0.5	7
15	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Advances, 2021, 5, 5098-5106.	2.5	46
16	How Coronavirus Disease 2019 Changed Dermatology Practice in 1 Year Around the World. Dermatologic Clinics, 2021, 39, 639-651.	1.0	3
17	Reasons we should not exclude the term parapsoriasis from the medical vocabulary. Journal of Cutaneous Pathology, 2021, 48, 1436-1437.	0.7	O
18	Development of a clinical scale to assess the severity of <i>striae distensae</i> . Skin Research and Technology, 2021, 27, 627-631.	0.8	2

#	Article	IF	CITATIONS
19	Characteristics associated with significantly worse quality of life in mycosis fungoides/SÃ $@$ zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index () Tj ETQq1 1 0.784314 rg	gBT‡Øverlo	ock7½0 Tf 50
20	Cutaneous manifestations of adult T-cell leukemia/lymphoma. Seminars in Diagnostic Pathology, 2020, 37, 81-91.	1.0	20
21	Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. Dermatology, 2020, 236, 117-122.	0.9	10
22	Extensive cutaneous involvement by dermatomyositis: Report of six cases and review of the literature. Autoimmunity Reviews, 2020, 19, 102680.	2.5	2
23	Trends in Melanoma Mortality in Brazil: A Registry-Based Study. JCO Global Oncology, 2020, 6, 1766-1771.	0.8	10
24	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European Journal of Cancer, 2020, 133, 120-130.	1.3	21
25	Progression of mycosis fungoides after treatment with dupilumab: A case report. Dermatologic Therapy, 2020, 33, e13880.	0.8	22
26	Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Scientific Reports, 2020, 10, 9774.	1.6	33
27	Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. Anais Brasileiros De Dermatologia, 2020, 95, 221-237.	0.5	22
28	Worse survival of invasive melanoma patients in men and "de novo―lesions. Anais Brasileiros De Dermatologia, 2020, 95, 158-164.	0.5	5
29	Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives. Anais Brasileiros De Dermatologia, 2019, 94, 313-319.	0.5	2
30	Dermoscopy of primary cutaneous B†and Tâ€cell lymphomas and pseudolymphomas presenting as solitary nodules and tumors: a caseâ€control study with histopathologic correlation. International Journal of Dermatology, 2019, 58, 1270-1276.	0.5	17
31	An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review. European Journal of Cancer, 2019, 119, S26-S27.	1.3	0
32	Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: an international virtual study. European Journal of Cancer, 2019, 119, S27-S28.	1.3	0
33	Velvety Palms. New England Journal of Medicine, 2019, 381, e35.	13.9	0
34	Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil. Diagnostic Pathology, 2019, 14, 115.	0.9	4
35	Atypical herpes vasculitis in a leukemic patient: An unusual presentation. Hematology, Transfusion and Cell Therapy, 2019, 41, 95-98.	0.1	1
36	The PROCLIPI international registry of earlyâ€stage mycosis fungoides identifies substantial diagnostic delay in most patients. British Journal of Dermatology, 2019, 181, 350-357.	1.4	127

#	Article	lF	Citations
37	Participation and responsibility. Anais Brasileiros De Dermatologia, 2019, 94, 8-8.	0.5	O
38	Consensuses, guidelines and position papers: the role of the Brazilian Society of Dermatology in the contribution to the best practice of Dermatology. Anais Brasileiros De Dermatologia, 2019, 94, 6-6.	0.5	0
39	Leprosy elimination - Still a long way to go. Sao Paulo Medical Journal, 2019, 137, 552-554.	0.4	1
40	Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression. International Journal of Dermatology, 2018, 57, 675-680.	0.5	2
41	Dermoscopic findings of perifollicular pigmentation associated with vandetanib. Dermatology Practical and Conceptual, 2018, 8, 340-341.	0.5	2
42	Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1486-1489.	0.4	4
43	Profile of dermatological consultations in Brazil (2018). Anais Brasileiros De Dermatologia, 2018, 93, 916-928.	0.5	33
44	Zwei FÇe perforierender Dermatosen bei Therapie mit Multikinaseâ€Inhibitoren, einer davon assoziiert mit Lenvatinib. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1486-1489.	0.4	1
45	Lymph node imaging in patch/plaque mycosis fungoides; enlarged LN are infrequent but lymphomatous nodal involvement may occur and upstage patients to advanced disease. European Journal of Cancer, 2018, 101, S25-S26.	1.3	0
46	Survival rates and hematological parameters of Sezary syndrome treated with chlorambucil or interferon: An acceptable alternative when photopheresis is not available? European Journal of Cancer, 2018, 101, S35.	1.3	0
47	Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sézary syndrome and those with more extensive skin involvement. European Journal of Cancer, 2018, 101, S39.	1.3	1
48	Clinicopathologic characteristics, prognostic and predictive biomarkers in adult T-cell leukemia/lymphoma (ATLL): A characterization of 79 cases from the Western Hemisphere. European Journal of Cancer, 2018, 101, S16.	1.3	0
49	Granulomatous slack skin: A series of cases. European Journal of Cancer, 2018, 101, S25.	1.3	0
50	Demographics and spatial distribution of the Brazilian dermatologists. Anais Brasileiros De Dermatologia, 2018, 93, 99-103.	0.5	6
51	Chronic activation profile of circulating CD8+ T cells in Sézary syndrome. Oncotarget, 2018, 9, 3497-3506.	0.8	21
52	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. Blood, 2018, 132, 1646-1646.	0.6	0
53	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, The, 2017, 390, 555-566.	6.3	444
54	Double-positive CD4 and CD8 Sézary syndrome. JAAD Case Reports, 2017, 3, 485-488.	0.4	3

#	Article	IF	CITATIONS
55	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	0.6	98
56	A case report of erythroderma in a patient with borderline leprosy on reversal reaction: a result of the exacerbated reaction?. BMC Dermatology, 2017, 17, 16.	2.1	4
57	Profile of differentially expressed Toll-like receptor signaling genes in the natural killer cells of patients with Sézary syndrome. Oncotarget, 2017, 8, 92183-92194.	0.8	6
58	Angiosarcoma in HIV-negative patients is not associated with HHV-8. Anais Brasileiros De Dermatologia, 2016, 91, 738-741.	0.5	2
59	Folliculotropic mycosis fungoides: clinical and epidemiological evaluation in a single center in Brazil. International Journal of Dermatology, 2016, 55, e256-61.	0.5	12
60	Hematopoietic stem cell transplantation for cutaneous Tâ€eell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil. Journal of Dermatology, 2016, 43, 638-642.	0.6	16
61	Adherence to topical therapies in actinic keratosis: A literature review. Journal of Dermatological Treatment, 2016, 27, 538-545.	1.1	14
62	Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndrome. Oncotarget, 2016, 7, 74592-74601.	0.8	8
63	Indeterminate cell histiocytosis successfully treated with phototherapy. Autopsy and Case Reports, 2016, 6, 33-38.	0.2	15
64	A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. International Journal of Dermatology, 2015, 54, 509-515.	0.5	32
65	Evaluation of the 2008 World Health Organization classification for non-mycosis fungoides, non-Sezary syndrome T/NK-cell lymphomas with primary cutaneous involvement. Journal of Cutaneous Pathology, 2015, 42, 965-973.	0.7	7
66	Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% $5\hat{a}\in \mathbb{R}$ luorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1822-1827.	1.3	27
67	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	0.8	328
68	Physician perceptions and experience of current treatment in actinic keratosis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 298-306.	1.3	23
69	<scp>D</scp> aylight photodynamic therapy for actinic keratoses in <scp>S</scp> ão <scp>P</scp> aulo, <scp>B</scp> razil. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 54-56.	0.7	30
70	Cutaneous lymphomas: A review. Cumhuriyet Medical Journal, 2015, 37, 67.	0.1	0
71	Loss of melanocytes in hypopigmented mycosis fungoides: a study of 18 patients. Journal of Cutaneous Pathology, 2014, 41, 101-107.	0.7	17
72	Inpatient dermatology: profile of patients and characteristics of admissions to a tertiary dermatology inpatient unit in $\langle scp \rangle S \langle scp \rangle A \delta c \langle scp \rangle P \langle scp \rangle aulo, \langle scp \rangle B \langle scp \rangle razil$. International Journal of Dermatology, 2014, 53, 685-691.	0.5	14

#	Article	IF	CITATIONS
73	Hypopigmented Mycosis Fungoides versus Mycosis Fungoides with Concomitant Hypopigmented Lesions: Same Disease or Different Variants of Mycosis Fungoides?. Dermatology, 2014, 229, 271-274.	0.9	13
74	Erythroderma: Searching for diagnostic clues in a series of 164 patients. Journal of the American Academy of Dermatology, 2014, 70, AB1.	0.6	1
75	A Pilot Split-Face Study Comparing Conventional Methyl Aminolevulinate-Photodynamic Therapy (PDT) With Microneedling-Assisted PDT on Actinically Damaged Skin. Dermatologic Surgery, 2013, 39, 1197-1201.	0.4	84
76	Coâ€presentation of human Tâ€cell lymphotropic virus type 1 (HTLVâ€1)â€associated myelopathy/tropical spastic paraparesis and adultâ€onset infective dermatitis associated with HTLVâ€1 infection. International Journal of Dermatology, 2013, 52, 63-68.	0.5	12
77	High Prevalence of Skin Disorders among HTLV-1 Infected Individuals Independent of Clinical Status. PLoS Neglected Tropical Diseases, 2013, 7, e2546.	1.3	29
78	Polymorphisms in the p27 kip-1 and prohibitin genes denote novel genes associated with melanoma risk in Brazil, a high ultraviolet index region. Melanoma Research, 2013, 23, 231-236.	0.6	9
79	Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. Anais Brasileiros De Dermatologia, 2013, 88, 954-960.	0.5	61
80	Ethnicity and Cutaneous Melanoma in the City of Sao Paulo, Brazil: A Case-Control Study. PLoS ONE, 2012, 7, e36348.	1.1	12
81	Pain in photodynamic therapy: mechanism of action and management strategies. Anais Brasileiros De Dermatologia, 2012, 87, 521-529.	0.5	41
82	European ancestry and polymorphisms in DNA repair genes modify the risk of melanoma: A case–control study in a high UV index region in Brazil. Journal of Dermatological Science, 2011, 64, 59-66.	1.0	32
83	DNA damage and repair in leukocytes of melanoma patients exposed in vitro to cisplatin. Melanoma Research, 2011, 21, 99-105.	0.6	8
84	Microvascular Lymphatic Density Analysis in Cutaneous Regressive and Nonregressive Superficial Spreading Melanomas Using the Lymphatic Marker D2-40. American Journal of Dermatopathology, 2011, 33, 669-674.	0.3	2
85	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. Blood, 2011, 118, 4024-4035.	0.6	365
86	<i>PTCH1</i> gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas. International Journal of Dermatology, 2011, 50, 838-843.	0.5	5
87	Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 2011, 29, 2598-2607.	0.8	550
88	Genomic instability in human actinic keratosis and squamous cell carcinoma. Clinics, 2011, 66, 523-8.	0.6	4
89	Polymerase chain reaction-Based clonality analysis of cutaneous B-cell lymphoproliferative processes. Clinics, 2010, 65, 53-60.	0.6	13
90	Reações tegumentares adversas relacionadas aos agentes antineoplásicos: parte I. Anais Brasileiros De Dermatologia, 2010, 85, 425-437.	0.5	15

#	Article	IF	CITATIONS
91	Reações tegumentares adversas relacionadas aos agentes antineoplásicos: parte II. Anais Brasileiros De Dermatologia, 2010, 85, 591-608.	0.5	18
92	Systemic Treatment in Severe Cases of Recurrent Aphthous Stomatitis: An Open Trial. Clinics, 2009, 64, 193-198.	0.6	45
93	Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream. Clinics, 2009, 64, 961-966.	0.6	62
94	Human Tâ€eell lymphotropic virus type 1 infective dermatitis emerging in adulthood. International Journal of Dermatology, 2009, 48, 723-730.	0.5	30
95	Primary Cutaneous Blastoid Mantle Cell Lymphoma-Case Report. American Journal of Dermatopathology, 2009, 31, 398-400.	0.3	31
96	Mammary and extramammary paget's disease: a study of 14 cases and the associated therapeutic difficulties. Clinics, 2009, 64, 599-606.	0.6	29
97	High numbers of human skin cancers express MMP2 and several integrin genes. Journal of Cutaneous Pathology, 2008, 35, 285-291.	0.7	20
98	Disseminated blue naevus and malignant blue naevus associated with excessive aromatase syndrome. Clinical and Experimental Dermatology, 2008, 33, 591-594.	0.6	7
99	Cutaneous melanoma: descriptive epidemiological study. Sao Paulo Medical Journal, 2008, 126, 41-47.	0.4	28
100	Clinical and serological follow-up studies of endemic pemphigus foliaceus (fogo selvagem) in Western Parana, Brazil (2001-2002). British Journal of Dermatology, 2006, 155, 446-450.	1.4	19
101	Epidermal Nevus Syndrome Associated with Adnexal Tumors, Spitz Nevus, and Hypophosphatemic Vitamin D-Resistant Rickets. Pediatric Dermatology, 2005, 22, 48-54.	0.5	19
102	Nucleolar organizer region staining patterns in paraffin-embedded tissue cells from human skin cancers. Journal of Cutaneous Pathology, 2005, 32, 323-328.	0.7	20
103	Genomic instability in basal cell carcinomas. Journal of Dermatological Science, 2005, 39, 186-188.	1.0	5
104	Ribosomal DNA exhibits few alterations in human skin cancers. Journal of Dermatological Science, 2004, 34, 109-111.	1.0	2
105	Repetitive DNA alterations in human skin cancers. Journal of Dermatological Science, 2004, 36, 79-86.	1.0	15
106	Histopathological and immunohistochemical assessment of acquired ichthyosis in patients with human T-cell lymphotropic virus type I-associated myelopathy. British Journal of Dermatology, 2003, 149, 776-781.	1.4	24
107	Acrodermatitis Enteropathica: Case Report and Review of the Literature. Pediatric Dermatology, 2002, 19, 426-431.	0.5	153
108	Necrolytic migratory erythema associated with glucagonoma syndrome: a case report. Revista Do Hospital Das Clinicas, 2001, 56, 183-188.	0.5	5

#	Article	IF	CITATIONS
109	Direct immunofluorescence in Lupus Erythematosus (LE). Sao Paulo Medical Journal, 1996, 114, 1141-1147.	0.4	7
110	Pemphigus foliaceus autoantibodies bind both epidermis and squamous mucosal epithelium, but tissue injury is detected only in the epidermis. Journal of the American Academy of Dermatology, 1994, 31, 954-958.	0.6	19
111	Environmental Risk Factors in the Endemic Pemphigus Foliaceus (Fogo Selvagem). Journal of Investigative Dermatology, 1992, 98, 847-850.	0.3	82
112	Endemic pemphigus foliaceus in western Parana, Brazil (1976-1988). British Journal of Dermatology, 1990, 123, 431-437.	1.4	18